2026

Million

Form

<h3 id="key-highlights">Key Highlights</h3>
<ul>
 <li>CervoMed (CRVO) shares surged 32.3% during premarket hours Tuesday following disclosure of a significant director transaction</li>
 <li>Board member Joshua Boger acquired 955,414 shares priced at $3.14 each on June 11 through a private placement arrangement</li>
 <li>The investment totaled approximately $3 million, executed via the Joshua S. Boger 2021 Trust</li>
 <li>The placement structure included one common share plus two warrant series (B and C) per unit</li>
 <li>Wall Street firm H.C. Wainwright maintains a Buy recommendation with a $25.00 target price on CRVO shares</li>
</ul>
Shares of CervoMed (CRVO) experienced a dramatic 32.3% surge in premarket activity Tuesday morning following the disclosure of a substantial stock purchase by board director Joshua Boger in a Form 4 regulatory filing.
<a href="https://knockoutstocks.com/stock/CRVO" rel="noopener noreferrer nofollow"> <img src="https://knockoutstocks.com/api/stocks/CRVO/embed" alt="CRVO Stock Card"> CervoMed Inc., CRVO </a>
Acting through the Joshua S. Boger 2021 Trust, Boger acquired 955,414 shares priced at $3.14 each on June 11. The aggregate value of this transaction reached approximately $3 million.
Prior to this filing becoming public, the stock had faced significant headwinds. CRVO shares were changing hands at $2.48 before the announcement, representing a decline of roughly 15% during the previous week and a steeper 70% pullback over the trailing six-month period.
This acquisition formed part of a private placement offering that CervoMed anticipates will yield approximately $10.5 million in total gross proceeds. The arrangement was structured through a securities purchase agreement executed on June 9 involving Boger’s trust alongside additional accredited investors.
The placement’s unit structure featured one common stock share accompanied by one Series B warrant and one Series C warrant. Series B warrants feature a $3.32 strike price, become exercisable immediately, and remain valid through June 11, 2031. Series C warrants carry a $3.14 exercise price, are similarly exercisable right away, and expire on June 11, 2027.
Notably, Chief Executive Officer John J. Alam also took part in this financing round, making it a particularly significant insider-backed transaction at the executive level.
<h3 id="updated-ownership-position">Updated Ownership Position</h3>
After completing this transaction, Boger’s total position includes 1,795,865 shares held indirectly via two separate trusts — the JSB 2021 Trust and The Amy S. Boger 2021 Trust — along with an additional 216,817 shares owned directly.
The warrant agreements contain an ownership limitation provision. Boger and related entities are restricted from exceeding 19.99% ownership of CervoMed’s total outstanding common stock when exercising these warrants. Should exercising approach this ceiling, he has the option to instead receive pre-funded warrants subject to identical restrictions.
Before Tuesday’s premarket rally, CervoMed carried a market capitalization of $23.42 million. According to InvestingPro’s valuation analysis, fair value stands at $3.40, indicating the stock had been trading beneath that benchmark entering Tuesday’s session.
<h3 id="wall-street-perspective">Wall Street Perspective</h3>
H.C. Wainwright has reaffirmed its Buy rating on CRVO stock with a price objective of $25.00. This recommendation followed CervoMed’s presentation of findings from its Phase 2b RewinD-LB clinical study evaluating neflamapimod at the AD/PD 2026 Conference.
The ongoing trial is assessing neflamapimod’s effectiveness in treating dementia with Lewy bodies. Results from the study indicated that participants exhibiting reduced plasma pTau181 levels experienced more pronounced clinical improvements from the therapeutic intervention.
In separate corporate news, CervoMed stockholders granted approval to all measures presented at the company’s 2026 Annual Meeting, which included the selection of eight board directors. Boger secured re-election to his director position during this voting process.
According to the Form 4 disclosure, Boger’s trust maintains ownership of 1,600,117 shares, while The Amy S. Boger 2021 Trust controls 195,748 shares, with Boger serving as sole trustee for both entities.
The post <a href="https://blockonomi.com/cervomed-crvo-surges-32-as-director-purchases-3-million-in-shares/" rel="noopener noreferrer nofollow">CervoMed (CRVO) Surges 32% as Director Purchases $3 Million in Shares</a> appeared first on <a href="https://blockonomi.com" rel="noopener noreferrer nofollow">Blockonomi</a>.

CervoMed (CRVO) Surges 32% as Director Purchases $3 Million in Shares

Table of Contents

Blockonomi

Other articles published on Jun 16, 2026

Join our free newsletter for daily crypto updates!